Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results

Core Insights - Quoin Pharmaceuticals has made significant advancements in its clinical programs, particularly for Netherton Syndrome and Peeling Skin Syndrome, with positive data emerging from ongoing studies [2][3][4] - The company closed a private placement financing in October 2025, raising up to $105.3 million to support operations and R&D efforts [1][4] - Sally Lawlor has been appointed as CFO to enhance the company's financial operations and support its commercialization strategy [1][3][7] Financial Highlights - As of September 30, 2025, Quoin reported a net loss of approximately $3.9 million for the third quarter and $11.5 million for the nine months, an increase from $2.3 million and $6.7 million in the same periods of 2024 [11][17] - The company had approximately $5.4 million in cash and cash equivalents, which, along with the recent financing, is expected to support operations into 2027 [10][11] - Operating expenses for the third quarter totaled approximately $4.0 million, with research and development costs significantly increasing compared to the previous year [17] Clinical and Regulatory Developments - The FDA awarded orphan drug designation to QRX003 for Netherton Syndrome, and pivotal studies for this treatment are set to begin enrollment in Q4 2025 [1][4] - The pediatric clinical program for Netherton Syndrome has been expanded based on positive long-term safety and efficacy data [1][2] - The NETHERTON NOW awareness campaign has gained significant traction, achieving over 1.5 million views within six months of its launch [1][8]